Jagsonpal Pharmaceuticals Limited — Board Meeting, 26-07-2025: Outcome of Board Meeting

Jagsonpal Pharmaceuticals' board approved financial results for the quarter ended June 30, 2025. The company reported revenue of ₹78.34 Cr and a net profit of ₹10.85 Cr for the quarter. The board had previously put forward a final dividend of ₹2.5 per share (₹6.60 Cr total) for FY25, pending AGM approval. Additionally, Sachin Jain ceased as CFO post-quarter, with a new CFO search underway. The company also allotted 127,850 equity shares under its ESOP plan.